摘要目的 探讨小剂量低分子肝素抗凝治疗对急性胰腺炎(AP)患者的影响.方法 收集2002年至2008年住院治疗的98例AP患者,按数字表法随机分为抗凝治疗组(40例)和常规治疗对照组(58例).治疗组包括重症急性胰腺炎(SAP)15例和轻症急性胰腺炎(MAP)25例;对照组包括SAP19例和MAP 39例.对照组常规治疗,治疗组在常规治疗的基础上给予低分子肝素3 000 U皮下注射,每12 h一次,持续2周.观察各组患者治疗前后APACHEⅡ评分、并发症发生率、病死率和平均住院天数,以及治疗组的出凝血指标变化.结果 治疗组中SAP患者治疗后7 d的APACHEⅡ评分、并发症发生率、病死率和住院天数分别为9.9±4.9、20%、13.3%和(20.6±10.4)d;对照组SAP患者分别为12.2±4.8、42.1%、47.4%和(28.2±12.5)d,两组差异均有统计学意义(P<0.05).而治疗组和对照组的MAP患者之间上述指标的差异均无统计学意义.治疗组应用低分子肝素前后出凝血指标变化也无统计学意义.结论 小剂量低分子肝素能降低sAP患者并发症发生率和病死率,缩短住院时间,不引起出血并发症,建议早期应用.

abstractsObjective To investigate the effect of low dose low molecular weight heparin (LMWH) on acute pancreatitis (AP). Methods 98 AP patients who were admitted in our hospital from 2002 to 2008 were randomly divided into anticoagulant therapy group (n = 40) and control group (n = 58). Anticoagulant therapy group consisted of 15 cases of severe acute pancreatitis (SAP) and 25 cases of mild acute pancreatitis (MAP) ; while there were 19 cases of SAP and 39 cases of MAP in control group. The patients of control group received conventional treatment, and conventional therapy together with 3 000 U LMWH subcutaneous injection every 12 hours were used in anticoagulant therapy group for two weeks. The changes of APACHE II score, complication rate, mortality and length of hospital stay were observed and the coagulation changes before and after anticoagulant therapy were documented. Results 7 days later, the APACHE II score, complication rate, mortality and length of hospital stay of SAP patients in the anticoagulant therapy group were 9. 9 ±4. 9, 20% , 13.3% , (20.6 ±10.4)d, respectively; while they were 12. 2 ±4.8, 42. 1%, 47.4%, (28. 2 ± 12. 5) d, respectively, in the control group, and the difference was statistically significant (P < 0. 05). The corresponding values were not statistically significantly different among MAP patients in the two groups. The coagulation after treatment in anticoagulant therapy group was not statistically different with that before treatment. Conclusions Low dose LMWH could reduce the rate of complication rate, mortality and decrease the length of hospital stay, without complication of hemorrhage, which should be recommended in the early phase of SAP.